Outcomes of Diffuse Large B-Cell Non-Hodgkin’s Lymphoma After Gemcitabine-Based Second Salvage Chemotherapy: A Single-Center Study

Background Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma with a five-year survival of 60%-70% with chemoimmunotherapy consisting of the R-CHOP combination (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone), with a relapse/refractory r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhatial, Mussadique Ali, Khan, Manzoor, Rab, Saif ur, Shaikh, Naila, Loohana, Chandumal, Imam Bokhari, Syed W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684307/
https://www.ncbi.nlm.nih.gov/pubmed/34934569
http://dx.doi.org/10.7759/cureus.19699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684307/
https://www.ncbi.nlm.nih.gov/pubmed/34934569
http://dx.doi.org/10.7759/cureus.19699

Ejemplares similares